Pregnancy and the Postpartum Period in Hodgkin Lymphoma: Impact on Disease Outcomes and Infectious Risk—A Multicenter Retrospective Study

Background/Objectives: Hodgkin lymphoma (HL) is the most common hematological malignancy among women of reproductive age. However, data on disease outcomes and infectious complications in pregnancy-associated HL are limited. No prior study has examined patients treated exclusively in the postpartum period. Our objective was to assess whether pregnancy-associated HL is associated with poorer disease outcomes and an increased risk of infectious complications. Methods: A multicenter, retrospective matched cohort study included 13 women diagnosed with HL during pregnancy or within 12 months postpartum (pregnancy-associated, PA) and 22 matched non-pregnancy-associated (NPA) controls. Controls were matched by International Prognostic Score, Ann Arbor stage, and age (within ±5 years), with diagnoses made between 2016 and 2025. Conditional logistic regression and mixed-effects Poisson regression were used to analyze infectious episodes separately for first-line and subsequent treatments. Progression-free survival (PFS) was estimated using the Kaplan–Meier method. Results: During first-line therapy, the PA group demonstrated significantly higher odds of any infection (OR 5.47, 95% CI 1.11–26.88, p = 0.037) and a higher number of infectious episodes (IRR 3.11, 95% CI 1.73–5.62, p < 0.001). No statistically significant differences were observed during subsequent lines of treatment. Progressive disease following first-line therapy was more frequent in the PA group (38.5% vs. 9.1%, p = 0.0559). Progression-free survival (PFS) at 12 months was 52.7% (95% CI 19.0–78.2) in the PA group compared to 77.3% (95% CI 53.7–89.8) in the NPA group (log-rank p = 0.27). No deaths were reported in either group. Conclusions: Pregnancy-associated HL is linked to a higher risk of infectious complications during first-line treatment and an increased rate of primary progression. These findings support the need for closer infectious surveillance in this population and should be confirmed in larger cohorts.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-13
DOI
https://doi.org/10.3390/jcm15228884
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pregnancy and the Postpartum Period in Hodgkin Lymphoma: Impact on Disease Outcomes and Infectious Risk—A Multicenter Retrospective Study

Sorina Nicoleta BADELITA, Camelia Marioara Dobrea, Andra Matei, Daniel Coriu et al.
2 links
Journal of Clinical Medicine
Lymphoma Diagnosis and Treatment
article

Pregnancy and the Postpartum Period in Hodgkin Lymphoma: Impact on Disease Outcomes and Infectious Risk—A Multicenter Retrospective Study

Sorina Nicoleta BADELITA, Camelia Marioara Dobrea, Andra Matei, Daniel Coriu, Daniel Nicolae MURARIU, Iulia Ursuleac, Oana Diana Preda, Larisa Emilia Zidaru, Simona Raluca Iacoban, Sanziana BARBU, Bianca CONSTANTIN, Andreea-Lacramioara Mohorea-Neata, Bianca TARAU, Ioana Loredana Cirlan, Florentina-Adriana Găuianu
article en

Abstract

Background/Objectives: Hodgkin lymphoma (HL) is the most common hematological malignancy among women of reproductive age. However, data on disease outcomes and infectious complications in pregnancy-associated HL are limited. No prior study has examined patients treated exclusively in the postpartum period. Our objective was to assess whether pregnancy-associated HL is associated with poorer disease outcomes and an increased risk of infectious complications. Methods: A multicenter, retrospective matched cohort study included 13 women diagnosed with HL during pregnancy or within 12 months postpartum (pregnancy-associated, PA) and 22 matched non-pregnancy-associated (NPA) controls. Controls were matched by International Prognostic Score, Ann Arbor stage, and age (within ±5 years), with diagnoses made between 2016 and 2025. Conditional logistic regression and mixed-effects Poisson regression were used to analyze infectious episodes separately for first-line and subsequent treatments. Progression-free survival (PFS) was estimated using the Kaplan–Meier method. Results: During first-line therapy, the PA group demonstrated significantly higher odds of any infection (OR 5.47, 95% CI 1.11–26.88, p = 0.037) and a higher number of infectious episodes (IRR 3.11, 95% CI 1.73–5.62, p < 0.001). No statistically significant differences were observed during subsequent lines of treatment. Progressive disease following first-line therapy was more frequent in the PA group (38.5% vs. 9.1%, p = 0.0559). Progression-free survival (PFS) at 12 months was 52.7% (95% CI 19.0–78.2) in the PA group compared to 77.3% (95% CI 53.7–89.8) in the NPA group (log-rank p = 0.27). No deaths were reported in either group. Conclusions: Pregnancy-associated HL is linked to a higher risk of infectious complications during first-line treatment and an increased rate of primary progression. These findings support the need for closer infectious surveillance in this population and should be confirmed in larger cohorts.

Journal of Clinical MedicineVol. 15(22)
Carol Davila University of Medicine and Pharmacy (RO), Medicover (DE), Institutul Clinic Fundeni (RO)
Good health and well-being
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon